The BICD2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population engineered from the A-549 human lung adenocarcinoma cell line. This product provides a heterogeneous loss-of-function model in which the BICD2 gene is disrupted across the cell pool, enabling robust interrogation of dynein-mediated intracellular trafficking without clonal selection artifacts.
The A-549 parental cell line was derived from the lung carcinoma tissue of a 58-year-old Caucasian male and displays an adherent epithelial morphology. Widely utilized as a model system, A-549 cells are instrumental in lung cancer research, encompassing studies of oncogenic signaling, drug resistance mechanisms, metabolic reprogramming, and host responses to respiratory viral and bacterial pathogens. This well-characterized background ensures reliable and reproducible experimental outcomes.
BICD2 encodes an adaptor protein essential for retrograde cargo transport along microtubules. It physically links the dynein-dynactin motor complex to cargo organelles, including RAB6-positive vesicles and LAMP1-positive late endosomes/lysosomes, through direct interactions with RAB6 and the dynein intermediate chain. BICD2 activity is modulated by phosphorylation via upstream kinases CDK5 and PLK1, and it functions downstream to scaffold NDE1, NDE2, and LIS1 into complexes that drive nuclear migration and Golgi apparatus positioning. Notably, the BICD2-NDE1-LIS1 tripartite complex is crucial for centrosome-nucleus coupling during cell migration, while BICD2-RAB6 interactions regulate Golgi ribbon maintenance and secretory vesicle motility.
Within the A-549 lung cancer context, BICD2 disruption permits detailed analysis of how retrograde transport defects influence epithelial tumor cell biology. Loss of BICD2 function is expected to impair Golgi organization, disrupt vesicular trafficking of signaling molecules, and alter nuclear positioning, thereby affecting processes such as cell cycle progression, directed migration, and proliferation. Consequently, this knockout model serves as a powerful tool for investigating the role of cytoskeletal coordination in lung adenocarcinoma pathogenesis and for exploring therapeutic vulnerabilities linked to dynein dysfunction.
Typical downstream assays include western blotting to verify BICD2 depletion, immunofluorescence microscopy to visualize Golgi fragmentation and vesicle accumulation, co-immunoprecipitation to assess dynein-dynactin assembly, RT-qPCR to quantify residual BICD2 mRNA, and live-cell imaging of RAB6-labeled cargo dynamics. The product is well suited for functional characterization of BICD2 interactors, mechanistic studies of neurodegenerative disorders such as SMALED2 and hereditary spastic paraplegia, and drug screens targeting motor neuron diseases. Additionally, these polyclonal knockout cells can be employed in synthetic lethality screens to identify genes that become essential upon disruption of retrograde transport. For further technical information or ordering assistance, please contact Ascent Research.
